Physician-Scientist-Executive; Chief Medical Officer
Jason Luke, MD, FACP, FASCO
Loading...
The CheckPoints are ready to party - join us tonight Sunday June 1 at Buddy Guys! Best party of #ASCO25 & all for the great cause of the @sitcancer.bsky.social Forward Fund that supports post-doc & trainee awards. See you tonight!!!
Extremely excited re: IMA203 - PRAME TCR T cells Ph 1 study published in @natmedicine.bsky.social! This is a transformative Rx in #melanoma for HLA-A201+ & PD1 refractory pts. Compared to TIL, easier to make, less toxic & so far ~2x response rate in heavily pre-Rx.
www.nature.com/articles/s41...
Time for the #AACR25 Annual Reception, featuring the #Checkpoints! Be there tonight 830 PM at McCormick Place West (Level 3) in the Skyline Ballroom (W375). We have a bunch of new tunes & rehearsal was great! @theaacr.bsky.social
Podcast alert! Enjoyed discussing #ASCO25 #Immunotherapy & #Melanoma data w Dr. Diwakar Davar. Important studies that are advancing the field! @ascocancer.bsky.social
dailynews.ascopubs.org/do/podcast-i...
Talking IMA203 & SUPRAME trial #iwCART25 in Miami last wknd. Pass the word to #melanoma patients needing novel therapeutics. After ICI, this therapy has possibility for long-term dz control! Trial opening in USA & Europe. 1st pt got IMA203 in Pittsburgh last week!
clinicaltrials.gov/study/NCT067...
A @sitcancer.bsky.social vision statement on accelerating #clinicaltrials to get 100 immunotherapy regulatory approvals in 10 years. Excited to be part of this effort for the paper, for our field but most importantly for the people with #cancer we are working to #cure!
jitc.bmj.com/content/13/3...
Nature research paper: Humoral determinants of checkpoint immunotherapy
go.nature.com/41a8fin
Excited to help lead Phase 2/3 frontline metastatic #melanoma TeLuRide-006 study of pembro +/- novel IV TLR7/8 agonist EIK1001. Super interesting pre-clinical & prelim responses in PD1 refractory dz. Trial is open in #Pittsburgh & globally for accrual!
clinicaltrials.gov/study/NCT066...
Appreciate the profile www.statnews.com/pharmalot/20... from Ed Silverman & @statnews.com! Amazing progress at Strand Therapeutics advancing field leading genetic medicines. Check my quote on being a nutating mixer if I were a piece of lab equipment ;)
#synbio #immunotherapy #cancerresearch
VIP tickets are available now! The CheckPoints will be back in Chicago on June 1 at Buddy Guy’s Legends. Donations will support SITC’s Forward Fund and benefit the next generation of cancer immunotherapy experts. LEARN MORE: www.sitcancer.org/funding/the-... #RockinForACure
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Jason Luke, MD, FACP, FASCO
Nature
Jason Luke, MD, FACP, FASCO
Society for Immunotherapy of Cancer
Rapid extracellular antibody profiling reveals a contribution of autoantibodies to the effectiveness of checkpoint immunotherapy for cancer.
